Semaglutide is a GLP-1 receptor agonist that mimics natural gut hormones to reduce hunger, slow digestion, and improve insulin levels
Its site carries a disclaimer saying the products are 'for research purposes only
Some peptides tolerate a single freeze, but repeated freeze-thaw cycles damage most
Manufacturing challenges: Semaglutide is a peptide-based drug, requiring complex synthesis and sterile production, which limits who can make it at scale
Novo Nordisk) can lead to ineffective treatment due to incorrect dosing, contamination, and the use of unknown ingredients, the World Health Organization (WHO) is warning
Currently, formulary-exclusions from branded manufacturers have relegated generics of exenatide and of liraglutide (first-generation GLP-1s which have already gone generic) to the overlooked and unknown in spite of years of proven efficacy